Notice Number: NOT-CA-17-060
Release Date: May 11, 2017
Estimated Publication Date of Announcement: July 2017
First Estimated Application Due Date: December 2017
Earliest Estimated Award Date: June 2018
Earliest Estimated Start Date: July 2018
National Cancer Institute (NCI)
The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on liver cancer to improve the surveillance of liver cancer in high risk populations, increase the fraction of liver cancer detected at an early stage and to better stratify patients at risk of developing liver cancer. To achieve these objectives, this initiative will support the formation of a Translational Liver Cancer Consortium. The Consortium will be expected to work collaboratively toward improved early detection of liver cancer.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in the Summer of 2017 with an expected application due date in Fall of 2017.
This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.
This Notice encourages investigators with expertise and insights in translational research of liver cancer to begin to consider applying for this new FOA. The investigators will be expected to work collaboratively toward improved early detection of liver cancer in high risk patient populations (e.g. cirrhosis) with different racial and ethnic backgrounds and with different etiologies (e.g. viral and non-viral).
In addition, collaborative investigations combining expertise in early detection, biomarkers, surveillance, imaging, and biorepositories will be encouraged and these investigators should also begin considering applying for this application. Among the areas of research encouraged in this initiative are stratification of high risk patient populations (e.g. patients with cirrhosis), identification of markers for patients with different liver disease etiologies (e.g. viral and non-viral), inclusion of high risk patients with different racial and ethnic backgrounds, changes in viral genome and associated risk of liver cancer.
To the extent possible, investigators will be expected to leverage resources from domestic and foreign collaborators with established relevant cohorts. There will be limited resources for the establishment of new patient cohorts so the leveraging or supplementing existing cohorts is encouraged.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Please direct all inquiries to:
Jo Ann Rinaudo, PhD
National Cancer Institute